Edotreotide

Edotreotide, namely 1,4,7,10 - tetraazacyclododecane - 1,4,7,10 - tetraacetic acid, is a powerful chelating agent capable of forming stable complexes with various metal ions such as gallium (Ga), indium (In), yttrium (Y), and lutetium (Lu). The octreotide moiety in edotreotide is a derivative of octreotide, in which phenylalanine (Phe) at the third position is replaced by tyrosine (Tyr), affecting its affinity for somatostatin receptors. It is often combined with radioisotopes such as lutetium - 177 (Lu - 177) or yttrium - 90 (Y - 90) for the treatment of somatostatin receptor - positive tumors, such as neuroendocrine tumors. The high - energy β - particles emitted by the radioisotopes can kill tumor cells. After binding with radioisotopes, it can be used in positron emission tomography (PET) or single - photon emission computed tomography (SPECT) imaging, helping doctors accurately determine the location and size of the tumor and evaluate the expression of somatostatin receptors in the tumor. Edotreotide can effectively bind to somatostatin receptors to achieve precise localization of the diseased site. It can be used under various experimental conditions. By binding to the somatostatin receptors on the surface of tumor cells, it can precisely target tumor cells and reduce damage to normal tissues.